cycloSal-pronucleotides of 2',3'-dideoxyadenosine and 2',3'-dideoxy- 2',3'-didehydroadenosine: Synthesis and antiviral evaluation of a highly efficient nucleotide delivery system

Journal of Medicinal Chemistry

Volumn 42, Issue 9, 1999, Pages 1604-1614

  Meier, Chris ^a,c   Knispel, Tina ^a,c   De Clercq, Erik ^b   Balzarini, Jan ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADENOSINE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE; CYCLO(3 METHYLSALIGENYL) 5' O (2',3' DIDEHYDROADENOSINYL)PHOSPHATE; CYCLO(3,5 DIMETHYLSALIGENYL) 5' O (2',3' DIDEOXY 2',3' DIDEHYDROADENOSINYL)PHOSPHATE; CYCLO(3,5 DIMETHYLSALIGENYL) 5' O (2',3' DIDEOXYADENOSINYL)PHOSPHATE; CYCLOSALIGENYL 5' O (2',3' DIDEOXY 2',3' DIDEOXY 2',3' DIDEHYDROADENOSINYL)PHOSPHATE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SYNTHESIS; HYDROLYSIS; LIPOPHILICITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ADENOSINE DEAMINASE; ADENOSINE MONOPHOSPHATE; AMP DEAMINASE; ANIMALS; ANTI-HIV AGENTS; CELL LINE; CELL TRANSFORMATION, VIRAL; DEOXYADENINE NUCLEOTIDES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HIV-1; HIV-2; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; MICE; PHOSPHORIC ACID ESTERS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 0033529048     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981096z     Document Type: Article

References (44)

1. (a) De Clercq, E. Chemotherapeutic Approaches of the Treatment of the Acquired Immunodeficiency Syndrome. J. Med. Chem. 1986, 29, 1561-1569.
2. (b) De Clercq, E. Towards improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.
3. (a) Balzarini, J. Metabolism and Mechanism of Antiretroviral Action of Purine and Pyrimidine Derivatives. Pharm. World Sci. 1994, 16, 113-126.
4. (b) Herdewijn, P.; Balzarini, J.; De Clercq, E. 2′,3′-Dideoxynucleoside Analogues as Anti-HIV Agents. In Advances in Antiviral Drug Design; De Clercq, E., Ed.; JAI Press Inc.: Greenwich, London, 1993; Vol. 1, pp 233-318.
5. (c) Balzarini, J.; Kang, G.-J.; Dalal, M.; Herdewijn, P.; De Clercq, E.; Broder, S.; Johns, D. G. The Anti-HTLV-III (Anti-HIV) and Cytotoxic Activity of 2′,3′-Didehydro-2′,3′-dideoxyribonucleosides: A Comparison with their Parental 2′,3′-Dideoxyribonucleosides. Mol. Pharmacol. 1987, 32, 162-167.
6. Johnson, M. A.; Ahluwalia, G.; Conelly, M. C.; Cooney, D. A.; Broder, S.; Johns, D. G.; Fridland, A. Metabolic Pathways for the Activation of the Antiretroviral Agent 2′,3′-Dideoxyadenosine in Human Lymphoid Cells. J. Biol. Chem. 1988, 263, 15354-15357.
7. Shelton, M. J.; O'Donell, M.; Morse, G. D.; Didanosine. Ann. Pharmacother. 1992, 26, 660-670.
8. Cooney, D. A.; Ahluwalia, G.; Mitsuya, J.; Fridland, A.; Johnson, M.; Hao, Z.; Dalal, M.; Balzarini, J.; Broder, S.; Johns, D. G. Initial Studies of the Cellular Pharmacology of 2′,3′-Dideoxyadenosine, an Inhibitor of HTLV-III Infection. Biochem. Pharmacol. 1987, 36, 1765-1768.
9. Carson, D. A.; Haertle, T.; Wasson, D. B.; Richman, D. D. Biochemical Genetic Analysis of 2′,3′-Dideoxyadenosine Metabolism in Human T Lymphocytes. Biochem. Biophys. Res. Commun. 1988, 151, 788-793.
10. Hao, Z.; Cooney, D. A.; Hartman N. R.; Perno, C. F.; Fridland, A.; DeVico, A. L.; Sarngadharan, M. G.; Broder, S.; Johns, D. G. Factors Determining the Activity of 2′,3′-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus in vitro. Mol. Pharmacol. 1988, 34, 431-435.
11. McGowan, J. J.; Tomaszewski, J.; Cracock, J.; Hoth, D.; Grieshaber, C. K.; Broderand, S.; Mitsuya, H. Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-Dideoxyadenosine. Rev. Infect. Dis. 1990, 12, S513-S521.
12. McLaren, C.; Datema, R.; Knupp, C. A.; Buroker, R. A. Didanosine. Antiviral Chem. Chemother. 1991, 2, 321-328.
13. Fridland, A.; Johnson, M. A.; Cooney, D. A.; Ahluwalia, G.; Marquez, V. E.; Driscoll, J. S.; Johns, D. G. Metabolism in Human Leukocytes of Anti-HIV Dideoxypurine Nucleosides. Ann. N.Y. Acad. Sci. 1990, 616, 205-216.
14. Ahluwalia, G.; Cooney, D. A.; Mitsuya, H.; Fridland, A.; Flora, K. P.; Hao, Z.; Dalal, M.; Broder, S.; Johns, D. G. Initial Studies on the Cellular Pharmacology of 2′,3′-Dideoxyinosine, an Inhibitor of HIV Infectivity. Biochem. Pharmacol. 1987, 36, 3797-3800.
15. Johnson, M. A.; Fridland, A. Phosphorylation of 2′,3′-Dideoxyinosine by Cytosolic 5′-Nucleotidase of Human Lymphoid Cells. Mol. Pharmacol. 1989, 36, 291-295.
16. Sommadossi, J. P. Nucleoside Analogues: Similarities and Differences. Clin. Infect. Dis. 1993, 16, S7-S15.
17. Gao, W. Y.; Shirasaka, T.; Johns, D. G.; Broder, S.; Mitsuya, H. Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells. J. Clin. Invest. 1993, 91, 2326-2333.
18. Nair, V.; Sells, T. B. Interpretation of the Roles of Adenylosuccinate Lyase and of AMP Deaminase in the Anti-HIV Activity of 2′,3′-Dideoxyadenosine and 2′,3′-Dideoxyinosine. Biochim. Biophys. Acta 1992, 1119, 201-204.
19. McGuigan, C.; Wedgwood, O.; De Clercq, E.; Balzarini, J. Phosphoramidate Derivatives of 2′,3′-Didehydro-2′,3′-dideoxyadenosine (d4A) Have Markedly Improved Potency and Selectivity. Bioorg. Med. Chem. Lett. 1969, 6, 2359-2362.
20. Perigaud, C.; Aubertin, A.-M.; Benzaria, S.; Pelicano, H.; Giradet, J.-L.; Maury, G.; Gosselin, G.; Kirn, A.; Imbach, J.-L. Equal Inhibition of the Replication of Human Immunodeficiency Virus in Human T-Cell Culture by ddA Bis(Sate)phosphotriester and 3′-Azido-2′,3′-dideoxythymidine. Biochem. Pharmacol. 1994, 48, 11-14.
21. Balzarini, J.; Kruining, J.; Wedgwood, O.; Pannecouque, C.; Aquaro, A.; Perno, C.-F.; Naesens, L.; Witrouw, M.; Heijtink, R.; De Clercq, E.; McGuigan, C. Conversion of 2′,3′-Dideoxyadenosine (ddA) and 2′,3′-Didehydro-2′,3′-dideoxyadenosine (d4A) to their Activity against Human Immunodeficiency Virus and Hepatitis B Virus. FEBS Lett. 1997, 410, 324-328.
22. (a) Meier, C. Pro-Nucleotides - Recent Advances in the Design of Efficient Tools for the Delivery of Biologically Active Nucleoaide Monophosphates. Synlett 1998, 233-242.
23. (b) Périgaud, C.; Giradet, J.-L.; Gosselin, G.; Imbach, J.-L. Comments on Nucleotide Delivery Forms. In Advances in Antiviral Drug Design; De Clercq, E., Ed.; JAI Press Inc.: Greenwich, London, 1996; Vol. 2, pp 147-172.
24. Meier, C. 4H-1.3.2-Benzodioxaphosphorin-2-nucleosyl-2-oxide - A New Concept for Lipophilic, Potential Prodrugs of Biologically Active Nucleoside Monophosphates. Angew. Chem. 1996, 108, 77-79; Angew. Chem., Int. Ed. Engl. 1996, 35, 70-72.
25. Meier, C. 4H-1.3.2-Benzodioxaphosphorin-2-nucleosyl-2-oxide - A New Concept for Lipophilic, Potential Prodrugs of Biologically Active Nucleoside Monophosphates. Angew. Chem. 1996, 108, 77-79; Angew. Chem., Int. Ed. Engl. 1996, 35, 70-72.
26. Meier, C.; Knispel, T.; Lorey, M.; Balzarini, J. CycloSal-Pro-Nucleotides: The Design and Biological Evaluation of a New Class of Lipophilic Nucleotide Prodrugs. Int. Antiviral News 1997, 5, 183-186.
27. (a) Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. cycloSal-d4TMP: Synthesis and Antiviral Evaluation of a New d4TMP Delivery System. J. Med. Chem. 1998, 41, 1417-1427.
28. (b) Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. Cyclic Saligenyl Phosphotriesters of 2′,3′-Dideoxy-2′,3′-didehydrothymidine (d4T) - A New Pro-Nucleotide Approach. Bioorg. Med. Chem. Lett. 1997, 7, 99-104.
29. Meier, C.; Knispel, T.; De Clercq, E.; Balzarini, J. ADA-Bypass by Lipophilic CycloSal-ddAMP Pro-Nucleotides. A Second Example of the Efficiency of the cycloSal-Concept. Bioorg. Med. Chem. Lett. 1997, 7, 1577-1582.
30. Liguori, A.; Perri, E.; Sidona, G.; Uccella, N. Regioselective 5′-O-Benzoylation of Deoxyadenosine with Benzoic Acid Catalyzed by N′,N′-Bis-(2-oxo-oxazolidin-3-yl)phosphordiamidic chloride (BOPDC). Tetrahedron 1988, 44, 229-234.
31. Ratnakar, R.; Talekar, P. L.; Coe, L.; Walker, R. T. An Efficient and General Synthesis of 5′-Esters of 2′,3′-Didehydro-2′,3′-Dideoxynucleosides: A Facile Opening of 2′,3′-Orthoacetates of Ribonucleosides Followed by Reductive Elimination of the Halogeno-acetates. Synthesis 1993, 303-306.
32. Webb, R. R., II; Wos, J. A.; Martin, J. C.; Brodfuehrer, P. R. Synthesis of 2′,3′-Dideoxyinosine. Nucleosides Nucleotides 1988, 7, 147-153.
33. Beach, J. W.; Kim, H. O.; Jeong, L. S.; Nampalli, S.; Islam, Q.; Ahn, S. K.; Babu, R.; Chu, C. K. A Highly Stereoselective Synthesis of Anti-HIV 2′,3′-Dideoxy- and 2′,3′-Didehydro-2′,3′-dideoxynucleosides. J. Org. Chem. 1992, 57, 3887-3894.
34. Chu, C. K.; Bhadti, V. S.; Doboszewski, B.; Gu, Z. P.; Kosugi, Y.; Pullaiah, K. C.; Van Roey, P. General Syntheses of 2′,3′-Dideoxynucleosides and 2′,3′-Didehydro-2′,3′-dideoxynucleosides. J. Org. Chem. 1989, 54, 2217-2225.
35. Meier, C.; De Clercq, E.; Balzarini, J. Nucleotide Delivery from cycloSaligenyl-3′-Azido-3′-Deoxythymidine Monophosphates (cyctoSal-AZTMP). Eur. J. Org. Chem. 1998, 837-846.
36. (a) Using a different methodology, a P value of 0.96 was determined for AZT: Balzarini, J.; Cools, J. M.; De Clercq, E. Estimation of the Lipophilicity of Anti-HIV Nucleoside Analogues by Determination of the Partition Coefficient and Retention Time on a LiChrosphere 60 RP-8 HPLC Column. Biochem. Biophys. Res. Commun. 1989, 158, 413-422.
37. (b) Lien, E. J.; Gao, H.; Prabhakar, H. Physical Factors Contributing to the Partition Coefficient and Retention Time of 2′,3′-Dideoxynucleoside Analogues. J. Pharm. Sci. 1991, 80, 517-521.
38. Also using a HPLC methodology, the log P values for AZT (0.05), ddA (-0.29), and ddI (-1.24) have been determined: Barchi, J. J.; Marquez, V. E.; Driscoll, J. S.; Ford, H., Jr.; Mitsuya, H.; Shirasaka, T.; Aoki, S.; Kelley, J. A. Potential Anti-AIDS Drugs. Lipophilic, Adenosine Deaminase-activated Prodrugs. J. Med. Chem. 1991, 34, 1647-1655.
39. Zimmermann, T. P.; Mahony, W. B.; Prus, K. L. 3′-Azido-3′-deoxythymidine, an Unusual Nucleoside Analogue that Permeates the Membrane of Human Erythrocytes and Lymphocytes by Nonfacilitated Diffusion. J. Biol. Chem. 1987, 262, 5748-5754.
40. Meier, C.; Habel, L.; Haller-Meier, F.; Lomp, A.; Herderich, M.; Klöcking, R.; Meerbach, A.; Wutzler, P. Chemistry and Anti-HSV-1 Evaluation of cycloSal-Nucleotides (cycloSal-NMP) of Acyclic Nucleoside Analogues. Antiviral Chem. Chemother. 1998, 9, in press.
41. York, J. L. Effect of the Structure of the Glycon on the Acid-Catalyzed Hydrolysis of Adenine Nucleosides. J. Org. Chem. 1981, 46, 2171-2173.
42. Bloch, A.; Robins, M. J.; McCarthy, J. R., Jr. The Role of the 5′-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase. J. Med. Chem. 1967, 10, 908-912.
43. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and pre-AIDS. Science 1984, 224, 497-600.
44. Balzarini, J.; Naesens, L.; Slachmuylders, J.; Niphuis, H.; Rosenberg, I.; Holy, A.; Schellekens, H.; De Clercq, E. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) Efficiently Inhibits Retrovirus Replication in vitro and Simian Immunodeficiency Virus Infection in Rhesus Monkeys. AIDS 1991, 5, 21-28.